Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly EBT Margin came in at 264.44% in Q4 2025, up 11528.0% YoY from N/an in Q4 2024, and up 451.95% on a QoQ basis from 75.14% in Q3 2025.
Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of EBT Margin data on file, last reported at 264.44% in Q4 2025.
- Quarterly EBT Margin rose 11528.0% year-over-year to 264.44% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2.47% (down 253.0% YoY) and the FY2025 annual result came in at 2.47%, down 253.0% from the prior year.
- EBT Margin grew to 264.44% in Q4 2025, from 75.14% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 300.22% in Q4 2023 to a low of 246.2% in Q1 2021.
- A 5-year average of 48.2% and a median of 87.31% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2021 — EBT Margin sank 29854 bps — and 2023, when it surged 41733 bps.
- Tracing KPTI's EBT Margin over 5 years: stood at 30.57% in 2021, then tumbled by 483 bps to 117.11% in 2022, then jumped by 356 bps to 300.22% in 2023, then plunged by 50 bps to 149.16% in 2024, then jumped by 77 bps to 264.44% in 2025.
- The last three EBT Margin figures came in at 264.44% (Q4 2025), 75.14% (Q3 2025), and 98.11% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -200.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.48% |
| Dec 31, 2025 | 264.44% |
| Sep 30, 2025 | -75.14% |
| Jun 30, 2025 | -98.11% |
| Mar 31, 2025 | -78.05% |
| Dec 31, 2024 | 149.16% |
| Sep 30, 2024 | -82.62% |
| Jun 30, 2024 | 55.76% |
| Mar 31, 2024 | -112.57% |
| Dec 31, 2023 | 300.22% |
| Sep 30, 2023 | -95.79% |
| Jun 30, 2023 | -86.49% |
| Mar 31, 2023 | -88.05% |
| Dec 31, 2022 | -117.11% |
| Sep 30, 2022 | -100.37% |
| Jun 30, 2022 | -123.34% |
| Mar 31, 2022 | -86.57% |
| Dec 31, 2021 | 30.57% |
| Sep 30, 2021 | -137.19% |
| Jun 30, 2021 | -236.49% |